# Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

> **NCT00144703** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 55 (—)

## Conditions studied

- Hematologic Malignancies
- Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00144703
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 55 (—)
- **Last updated:** 2012-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144703, "Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00144703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*